Physician profile
Gitana Bradauskaite
NPI 1902951304
$9,408.40
in general payments reported to CMS, 2019-2025
31 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $543 · 2021: $693 · 2022: $1,392 · 2023: $1,052 · 2024: $3,522 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,725 · Consulting Fee: $2,250 · Travel and Lodging: $34.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,724.97 |
| Consulting Fee | $2,250.00 |
| Travel and Lodging | $34.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $2,517.90 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $1,015.42 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $929.17 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $775.62 | 2019-2025 | Farxiga |
| Alexion Pharmaceuticals, INC. | $400.00 | 2021-2022 | |
| Ardelyx, INC. | $362.35 | 2024-2025 | Ibsrela |
| Amgen INC. | $340.67 | 2019-2025 | Tavneos, Parsabiv |
| Novartis Pharmaceuticals Corporation | $315.93 | 2024-2025 | |
| Akebia Therapeutics INC | $295.59 | 2019-2025 | Vafseo |
| Ani Pharmaceuticals, INC. | $283.17 | 2022-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $236.02 | 2023-2025 | Livtencity |
| Aurinia Pharma U.S., INC. | $233.78 | 2021-2024 | Lupkynis |
| Veloxis Pharmaceuticals, INC. | $223.37 | 2019-2024 | Envarsus |
| Genzyme Corporation | $193.73 | 2019-2023 | |
| Mallinckrodt Enterprises LLC | $165.79 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $141.94 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $131.11 | 2022-2023 | Benlysta |
| Janssen Pharmaceuticals, INC | $124.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $119.56 | 2024 | |
| Fresenius USA Marketing, INC. | $115.40 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $95.21 | 2021-2025 | Jynarque |
| Travere Therapeutics, INC. | $77.34 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.69 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $47.62 | 2024-2025 | Prevymis |
| Apellis Pharmaceuticals, INC. | $39.88 | 2025 | Empaveli |
| Chiesi USA, INC. | $39.40 | 2019 | |
| Baxter Healthcare | $33.69 | 2019-2020 | |
| Kyowa Kirin, INC. | $27.15 | 2024 | Crysvita |
| Oxford Immunotec USA INC | $25.46 | 2020 | |
| Cormedix INC. | $19.22 | 2025 | Defencath |
| Cumberland Pharmaceuticals, INC. | $13.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gitana Bradauskaite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.